Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
“in randomized, comparative clinical trials [24–28, 31, 32].”
BackgroundResultInfluentialSelf-citationMermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
“For empirical treatment of suspected catheter-related candidemia, use an echinocandin or, in selected patients, fluconazole A-II [186, 187, 194, 260] D ow naded rom http/academ ic.”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“Fluconazole remains standard therapy for selected patients with candidemia, on the basis of abundant data from welldesigned clinical trials [27, 28, 53, 79].”
BackgroundSelf-citationPappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Self-citationPappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
“Not surprisingly, invasive candidiasis was the most common IFI in each organ transplant type except among lung transplant recipients, and it was associated with a high overall mortality, similar to that seen in recent treatment trials of candidemia and other forms of invasive candidiasis [26–28].”
ResultSelf-citationSolomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
“Reboli et al 2007 [43] (245; 2003–2004) Anidulafungin 100 mg/d vs fluconazole 400 mg/d Randomized, double blinded Candidemia or invasive candidiasis Pregnancy $14 d after last positive blood culture Receipt of $1 d of antifungal drug and document fungal infection Clinical and microbiologic success at EOT All-cause dea…”
BackgroundSelf-citationTissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
“Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”
BackgroundMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationSolomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Surgical Infections · doi:10.1089/sur.2009.9930 · Cited by 623
“This observation, coupled with the common use of fluconazole prophylaxis in the intensive care unit, suggests empiric use of echinocandins (caspofungin, anidulafungin, and micafungin) [111–115].”
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
“com/ overview/surgical-infections/53/) [365].”
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525
Maertens, J., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W. J., Lass-Flörl, C., Ribaud, P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 470
Neofytos, D., Fishman, J. A., Horn, D., Anaissie, E., Chang, C.-H., Olyaei, A., Pfaller, M., Steinbach, W. J., Webster, K. M., & Marr, K. A. (2010) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2010.00492.x · Cited by 454
Catheter-related bloodstream infections
Gahlot, R., Gahlot, R., Nigam, C., Kumar, V., Yadav, G., Anupurba, S., Nigam, C., Kumar, V., Yadav, G., & Anupurba, S. (2014) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.134184 · Cited by 403
“[30] Antibiotic lock therapy should be used for catheter salvage; however, if antibiotic lock therapy cannot be used in this situation, systemic antibiotics should be administered through the colonized catheter.”
Kett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389
“Although recent guidelines recommend an echinocandin as the preferred class of agent in patients with moderately severe to severe illness Candida infections, only one trial comparing the echinocandin, anidulafungin, with fluconazole has shown greater efficacy than fluconazole with a trend toward improved survival (21).”
BackgroundSelf-citationPfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
“tion (FDA; years 2002 and 2006, respectively) for the treatment of invasive candidiasis, including candidemia (20, 40),”
BackgroundCurrent Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 377
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Invasive candidiasis as a cause of sepsis in the critically ill patient
Delaloye, J., & Calandra, T. (2014) · Virulence · doi:10.4161/viru.26187 · Cited by 372
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“The clinical evidence in support (or not) of combination therapy employing various antifungal agents for different IFIs has been recently reviewed,[177] yet there are no RCTs examining the efficacy of combination antifungal therapy.”
BackgroundResultInfluentialPrevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Self-citationHope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Pfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
“on the other hand received a marginally weaker recommendation (BIIt) because there were <3% neutropenic patients in this trial [97].”
Therapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
“On the basis of the data from initial controlled trial, ESCMID recommended deescalation after 10 days, as data were not available supporting any earlier timepoint [54].”
MethodStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
“However, they are shifted somewhat(1 log vs 3 logs) in susceptibility, which may account for sporadic reports of clinical failure [12,79].”
BackgroundCandidemia and invasive candidiasis in adults: A narrative review
Antinori, S., Milazzo, L., Sollima, S., Galli, M., & Corbellino, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.029 · Cited by 257
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
“In general, echinocandins (anidulafungin, caspofungin, and micafungin) have been tested for the treatment of candidemia in various controlled clinical trials [86, 110, 143], but the number of neutropenic patients in these trials was limited (max.”
BackgroundPatients at High Risk of Invasive Fungal Infections: When and How to Treat
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Drugs · doi:10.2165/00003495-200868140-00002 · Cited by 253
“The efficacy of the sites are shown in figure 3. echinocandins for antifungal prophylaxis will have Concerns have been raised regarding the deto be evaluated in future trials, even though their creased susceptibility of C. parapsilosis towards limitation to intravenous administration represents a echinocandins,[139] p…”
BackgroundInfluentialPfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
“gin-versus-fluconazole candidemia study (56), and 410 isolates were obtained”
BackgroundSelf-citationArendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.007 · Cited by 238
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
“The addition of the echinocandin class of antifungals marks a significant advance in therapy of these diseases, with enhanced safety and efficacy compared to previously available antifungal therapies (31, 36, 43, 52).”
BackgroundGroll, A. H., Pana, D., Lanternier, F., Mesini, A., Ammann, R. A., Averbuch, D., Castagnola, E., Cesaro, S., Engelhard, D., Garcia-Vidal, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30723-3 · Cited by 225
Azie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222
“A number of prospective RCTs published during the past decade have led to the validation of echinocandins and fluconazole for the treatment of IC and that of voriconazole for the treatment of IA (Herbrecht et al., 2002; Kullberg et al., 2005; Kuse et al., 2007; MoraDuarte et al., 2002; Pappas et al., 2007; Reboli et a…”
BackgroundSchmiedel, Y., & Zimmerli, S. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14281 · Cited by 218
Cornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., Thompson, G. R., & for the Mycoses Study Group Education and Research Consortium (MSG‐ERC) and the European Confederation of Medical Mycology (ECMM) (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 215
Ocular manifestations of candidemia
Oude Lashof, A. M. L., Rothova, A., Sobel, J. D., Ruhnke, M., Pappas, P. G., Viscoli, C., Schlamm, H. T., Oborska, I. T., Rex, J. H., & Kullberg, B. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir355 · Cited by 218
Self-citationBench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217
Treatment of Endogenous Fungal Endophthalmitis: Focus on New Antifungal Agents
Riddell, J., Comer, G. M., & Kauffman, C. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq204 · Cited by 217
Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598933 · Cited by 214
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationEchinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
van Asbeck, E. C., Clemons, K. V., & Stevens, D. A. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903213393 · Cited by 210
“The meaning of these higher MICs is still being investigated, but changes in the glucan synthase subunit Fks1 might explain the reduced activity of echinocandins against C. parapsilosis (Park et al. 2005; Reboli et al. 2007).”
BackgroundInfluentialMontravers, P., Mira, J.-P., Gangneux, J.-P., Leroy, O., & Lortholary, O. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03360.x · Cited by 206
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196
“However, this difference has not translated into consistent clinical failure (25, 38, 44), and the MIC breakpoint for”
BackgroundInvasive candidiasis: current clinical challenges and unmet needs in adult populations
Soriano, A., Honore, P. M., Puerta-Alcalde, P., Garcia-Vidal, C., Pagotto, A., Gonçalves-Bradley, D. C., & Verweij, P. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad139 · Cited by 190
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192
Self-citationClinical hepatotoxicity associated with antifungal agents
Kyriakidis, I., Tragiannidis, A., Munchen, S., & Groll, A. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1270264 · Cited by 187
Intensive care medicine research agenda on invasive fungal infection in critically ill patients
Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., Chakrabarti, A., Kett, D., Leon, C., Ostrosky-Zeichner, L., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4731-2 · Cited by 183
“While echinocandins appear superior to azoles in terms of treatment success [5], it is much more challenging to improve survival rates by applying a single diagnostic tool or treatment decision.”
BackgroundInfluentialSelf-citationColombo, A. L., Guimarães, T., Sukienik, T., Pasqualotto, A. C., Andreotti, R., Queiroz-Telles, F., Nouér, S. A., & Nucci, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3400-y · Cited by 183
“a randomized clinical trial [26] and a patient-level pooled analysis of randomized clinical trials [27], have shown”
MethodInitial antimicrobial management of sepsis
Niederman, M. S., Baron, R. M., Bouadma, L., Calandra, T., Daneman, N., DeWaele, J., Kollef, M. H., Lipman, J., & Nair, G. B. (2021) · Critical Care · doi:10.1186/s13054-021-03736-w · Cited by 180
Kullberg, B. J., Viscoli, C., Pappas, P. G., Vazquez, J., Ostrosky-Zeichner, L., Rotstein, C., Sobel, J. D., Herbrecht, R., Rahav, G., Jaruratanasirikul, S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy827 · Cited by 182
Self-citationInvasive candidiasis in critical care: challenges and future directions
Logan, C., Martin-Loeches, I., & Bicanic, T. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06240-x · Cited by 180
Invasive Fungal Infections in Solid Organ Transplant Recipients
Shoham, S., & Marr, K. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.28 · Cited by 178
Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 178
“The high mortality may be explained in part by a larger proportion of patients with severe underlying diseases but might have been reduced if an echinocandin was given more often as first-line treatment in the adult population, as recommended in official guidelines (5, 37, 43).”
BackgroundChaves, F., Garnacho-Montero, J., del Pozo, J. L., Bouza, E., Capdevila, J. A., de Cueto, M., Domínguez, M. Á., Esteban, J., Fernández-Hidalgo, N., Fernández Sampedro, M., et al. (2018) · Medicina Intensiva · doi:10.1016/j.medin.2017.09.012 · Cited by 170
Wang, J.-L., Chang, C.-H., Young-Xu, Y., & Chan, K. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01657-09 · Cited by 167
von Lilienfeld-Toal, M., Wagener, J., Einsele, H., Cornely, O. A., & Kurzai, O. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0271 · Cited by 164
Thompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1380 · Cited by 163
Self-citationNami, S., Aghebati-Maleki, A., Morovati, H., & Aghebati-Maleki, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.009 · Cited by 160
Aslam, S., Rotstein, C., & Practice, T. A. I. D. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13623 · Cited by 160
Self-citationAustin, P. C., Manca, A., Zwarenstein, M., Juurlink, D. N., & Stanbrook, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.002 · Cited by 159
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 160
“The echinocandins have become first-line therapy in many centers for the treatment of invasive candidiasis due to their proven efficacy, the infrequency of side effects, and the favorable drug interaction profile (12, 16, 20, 23).”
BackgroundArendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
“Additionally, anidulafungin has been associated with an improved success rate, even in cases involving fluconazolesusceptible species (39).”
BackgroundColombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., Queiroz‐Telles, F., Salles, M. J. C., da Cunha, C. A., Shikanai‐Yasuda, M. A., Moretti, M. L., & Nucci, M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.02.001 · Cited by 200
Kofla, G., & Ruhnke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-159 · Cited by 153
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
“,([205]) indicating the similarity in effectiveness of anidulafungin and fluconazole (mainstay for invasive fungal infections) in the treatment of invasive candidiasis.”
BackgroundCornely, O. A., Gachot, B., Akan, H., Bassetti, M., Uzun, Ö., Kibbler, C. C., Marchetti, O., de Burghgraeve, P., Ramadan, S., Pylkkänen, L., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ293 · Cited by 154
Thompson, G. R., Cadena, J., & Patterson, T. F. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.001 · Cited by 165
“Despite a greater response rate and a lower rate of death from all causes in the anidulafungin group, however, predetermined criteria for statistical superiority were not reached and only noninferior status granted.(87) It is common practice from the results of these trials for local resistance patterns and the severi…”
BackgroundRuhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 148
Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00478-08 · Cited by 134
“glabrata the lack of correlation between MIC and outcome is related to the very low MIC distribution observed in these clinical trials (29, 32, 37, 44).”
BackgroundThe risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos‐Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 140
García‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 143
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Arendrup, M. C., Arıkan-Akdağlı, S., Jørgensen, K. M., Barac, A. M., Steinmann, J., Toscano, C., Arsić-Arsenijević, V. S., Sartor, A., Lass‐Flörl, C., Hamprecht, A. G., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.08.001 · Cited by 153
Fernández-Ruiz, M., Aguado, J. M., Almirante, B., Lora-Pablos, D., Padilla, B., Puig-Asensio, M., Montejo, M., García-Rodríguez, J., Pemán, J., Ruiz Pérez de Pipaón, M., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu158 · Cited by 122
“To date, only 1 RCT has compared an echinocandin to an azole for the treatment of invasive candidiasis, concluding that anidulafungin was noninferior to fluconazole [13].”
Böhme, A., Ruhnke, M., Buchheidt, D., Cornely, O. A., Einsele, H., Enzensberger, R., Hebart, H. F., Heinz, W., Junghanß, C., Karthaus, M., et al. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0622-5 · Cited by 141
“Compared to D-AmB, fluconazole was not inferior and showed significantly better tolerability (AI) [2, 82, 90], but lower efficacy compared to anidulafungin [89].”
BackgroundResultAndes, D. R., Ambrose, P. G., Hammel, J., Wart, S. A. V., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 120
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117
“This class is characterized by favorable pharmacokinetics, few clinically relevant drug-drug interactions, safety in patients with end-organ dysfunction, and broad-spectrum anti-Candida activity (28, 31, 32, 39).”
BackgroundGuery, B. P., Arendrup, M. C., Auzinger, G. M., Azoulay, É., Borges-Sa, M., Johnson, E. M., Müller, E. E., Putensen, C., Rotstein, C., Sganga, G., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1339-6 · Cited by 123
“However, it should be noted that these models have not taken into account the results of the recent study suggesting a significantly better outcome with anidulafungin compared with fluconazole [21] which would justify a formal cost-effectiveness analysis comparing anidulafungin with fluconazole-based strategies.”
BackgroundResultInfluentialSelf-citationGarnacho‐Montero, J., Díaz‐Martín, A., García-Cabrera, E., de Pipaón, M. R. P., Hernandez-Caballero, C., & Lepe, J. A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks347 · Cited by 114
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“Anidulafungin was associated with a higher treatment success rate than was fluconazole, but mortality rates were not significantly different [22].”
BackgroundSiberry, G. K., Abzug, M. J., Nachman, S., Brady, M. T., Dominguez, K. L., Handelsman, E. L., MOFENSON, L. M., Nesheim, S. R., Health, N. I. O., Prevention, C. F. D. C. A., et al. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000437856.09540.11 · Cited by 119
Chau, M., Kong, D. C. M., van Hal, S. J., Urbancic, K. F., Trubiano, J. A., Cassumbhoy, M., Wilkes, J., Cooper, C. M., Roberts, J. A., Marriott, D. J. E., et al. (2014) · Internal Medicine Journal · doi:10.1111/imj.12600 · Cited by 116
Amornphimoltham, P., Yuen, P. S. T., Star, R. A., & Leelahavanichkul, A. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05581-y · Cited by 109
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A. L., Finquelievich, J. L., Barnes, R. A., & Wadula, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02122-07 · Cited by 107
“parapsilosis in clinical trials (25, 46, 54) suggest that this species should be carefully monitored with respect to emerging echinocandin resistance.”
BackgroundInfection of totally implantable venous access devices: A review of the literature
Pinelli, F., Cecero, E., Degl’Innocenti, D., Selmi, V., Giua, R., Villa, G., Chelazzi, C., Romagnoli, S., & Pittiruti, M. (2018) · The Journal of Vascular Access · doi:10.1177/1129729818758999 · Cited by 110
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Self-citationCandida Infections in Solid Organ Transplantation
Silveira, F. P., & Kusne, S. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12114 · Cited by 106
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
García‐Effrón, G., Chua, D. J., Tomada, J. R. T., DiPersio, J. R., Perlin, D. S., Ghannoum, M. A., & Bonilla, H. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 109
Candida in Solid Organ Transplant Recipients
Pappas, P. G., & Silveira, F. P. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02909.x · Cited by 105
Self-citationVazquez, J., Reboli, A. C., Pappas, P. G., Patterson, T. F., Reinhardt, J., Chin-Hong, P., Tobin, E., Kett, D. H., Biswas, P., & Swanson, R. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-97 · Cited by 101
“This included the study by Reboli and colleagues, which demonstrated higher response rates for anidulafungin compared to fluconazole for the treatment of C/IC [17].”
BackgroundResultInfluentialSelf-citationMellinghoff, S. C., Hoenigl, M., Koehler, P. A., Kumar, A., Lagrou, K., Lass‐Flörl, C., Meis, J. F. G. M., Menon, V. P., Rautemaa‐Richardson, R., & Cornely, O. A. (2018) · Mycoses · doi:10.1111/myc.12746 · Cited by 113
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.